Evidence map›Paper›PMID 19381833›Full record

ArticleAAPS PharmSciTech2009

Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations.

Abeer M Al-Ghananeem, Ahmad H Malkawi, Yahya M Muammer, Justin M Balko, Esther P Black, Walid Mourad, Edward Romond

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AAPS PharmSciTech, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  14. Nanotechnology: Future of Oncotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abeer M Al-GhananeemDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 927 Rose Street, Lexington, Kentucky 40536-0082, USA. amalg0@email.uky.edu
Ahmad H Malkawi
Yahya M Muammer
Justin M Balko
Esther P Black
Walid Mourad
Edward Romond

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the current study, novel paclitaxel-loaded cross-linked hyaluronan nanoparticles were engineered for the local delivery of paclitaxel as a prototype drug for cancer therapy. The nanoparticles were prepared using a desolvation method with polymer cross-linking. In vitro cytotoxicity studies demonstrated that less than 75% of the MDA-MB-231 and ZR-75-1 breast cancer cells were viable after 2-day exposure to paclitaxel-loaded hyaluronan nanoparticles or free paclitaxel, regardless of the dose. These results suggest that hyaluronan nanoparticles maintain the pharmacological activity of paclitaxel and efficiently deliver it to the cells. Furthermore, in vivo administration of the drug-loaded nanoparticles via direct intratumoral injection to 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumor in female rats was studied. The paclitaxel-loaded nanoparticles treated group showed effective inhibition of tumor growth in all treated rats. Interestingly, there was one case of complete remission of tumor nodule and two cases of persistent reduction of tumor size that was observed on subsequent days. In the case of free paclitaxel-treated group, the mean tumor volume increased almost linearly (R(2) = 0.93) with time to a size that was 4.9-fold larger than the baseline volume at 57 days post-drug administration. Intratumoral administration of paclitaxel-loaded hyaluronan nanoparticles could be a promising treatment modality for solid mammary tumors.

Indexed as

9,10-Dimethyl-1,2-benzanthraceneAnimalsAntineoplastic Agents, PhytogenicChemistry, PharmaceuticalFemaleHyaluronic AcidMammary Neoplasms, ExperimentalNanoparticlesPaclitaxelRatsRats, Sprague-DawleySolubility9,10-Dimethyl-1,2-benzanthraceneAntineoplastic Agents, PhytogenicHyaluronic AcidPaclitaxel

Identifiers

PMID19381833
PMCPMC2690785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.